NCT05143671

Brief Summary

Multidisciplinary team-approach in order to offer personalized treatments represents the emerging mainstream in cardiovascular medicine. "Hybrid operative rooms" allow to offer selected heart-disease patients truly "tailored" operations. This study wants to evaluate the effectiveness and safety of Hybrid Procedures in cardiac patients in three subgroups of patients:

  • Hybrid coronary revascularization strategy (coronary by-pass + PCI);
  • Hybrid valve and coronary disease correction (combination of surgical valve replacement and PCI);
  • Hybrid coronary and carotid artery disease treatment (combination of coronary by-pass and carotid stenting). The investigators hypothesize that morbidity might be reduced by 50% in hybrid procedures group as compared with predicted Society of Thoracic Surgery (STS) score.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
134

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 13, 2021

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

November 5, 2021

Completed
28 days until next milestone

First Posted

Study publicly available on registry

December 3, 2021

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2025

Completed
Last Updated

August 14, 2025

Status Verified

August 1, 2025

Enrollment Period

4.2 years

First QC Date

November 5, 2021

Last Update Submit

August 11, 2025

Conditions

Keywords

coronary artery diseasecarotid stenosispercutaneous coronary interventioncoronary artery bypasscarotid artery diseasesheart valvesstent

Outcome Measures

Primary Outcomes (8)

  • Number of participants with stroke

    Rapid onset of a new neurological deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection) that i) persists beyond 24 hours, or ii) less than 24 hours if: a) associated with infarction or hemorrhage on an imaging study, or b) treated with pharmacologic or mechanical intervention, or c) results in death.

    6 days after operation

  • Number of participants with renal failure

    Acute or worsening renal failure resulting in one or more of the following: 1. Increase of serum creatinine to ≥ 4.0 with an increase of at least 0.5mg/dl or 3x most recent preoperative creatinine level. 2. A new requirement for dialysis postoperatively.

    6 days after operation

  • Number of participants with prolonged ventilation > 24 hours

    Prolonged postoperative pulmonary ventilation \> 24.0 hours.

    25 hours after operative room exit.

  • Number of participants with deep sternal wound infection

    Deep sternal wound infection or mediastinitis (according to Centers for Disease Control (CDC) definition)

    Diagnosis within 30 days of the operation or >30 days after procedure but during hospital stay for surgery.

  • Number of participants who undergo reoperation

    Reoperation for bleeding/tamponade, valvular dysfunction, graft failure, aortic reintervention, or other cardiac reason.

    6 days after operation

  • Number of participants with major morbidity or operative mortality

    A composite endpoint defined as any of the outcomes listed in the first six rows of this list

    6 days after operation

  • Number of participants with short stay

    Patient length of stay \< 6 days. Discharged alive and within 5 days of surgery

    6 days after operation

  • Number of participants with long stay

    Patient length of stay \> 14 days. Failure to be discharged within 14 days of surgery

    15 days after operation

Secondary Outcomes (6)

  • Cardiovascular events

    30 days post procedure and 12 months

  • Bleeding

    30 days post procedure and 12 months

  • Rate of one or more additional adverse event.

    30 days post procedure and 12 months

  • Health Status through angina assessment.

    30 days post procedure and 12 months

  • Health Status through quality of life assessment.

    30 days post procedure and 12 months

  • +1 more secondary outcomes

Study Arms (3)

Hybrid coronary revascularization strategy (HCR)

Patients who undergo a combination of coronary artery bypass grafting and PCI.

Procedure: Coronary artery bypass graftingProcedure: Percutaneous coronary intervention

Hybrid valve and coronary disease correction

Patients who undergo a combination of surgical valve replacement and PCI.

Procedure: Percutaneous coronary interventionProcedure: Surgical valve replacement

Hybrid coronary and carotid artery disease treatment

Patients who undergo a combination of coronary artery bypass grafting and carotid stenting.

Procedure: Coronary artery bypass graftingProcedure: Carotid artery stenting

Interventions

Coronary artery bypass grafting in coronary revascularization.

Hybrid coronary and carotid artery disease treatmentHybrid coronary revascularization strategy (HCR)

Percutaneous coronary intervention in coronary revascularization.

Hybrid coronary revascularization strategy (HCR)Hybrid valve and coronary disease correction

Surgical mitral and / or aortic valve replacement.

Hybrid valve and coronary disease correction

Carotid artery stenting.

Hybrid coronary and carotid artery disease treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with: * Multi-vessel CAD involving the laft main (LM) and/or the left anterior descending (LAD) artery with indication for revascularization; * Severe, symptomatic valvular disease and CAD with indication for revascularization; * Significant unilateral carotid stenosis and CAD with indication for revascularization.

You may qualify if:

  • Signed informed consent, inclusive of release of medical information
  • Age ≥ 18 years
  • CAD with indication for revascularization
  • Coronary anatomy as follows:
  • Multivessel-CAD involving the left anterior descending (LAD) (proximal or mid) and/or the left main (LM) (ostial, mid-shaft or distal) with at least one further epicardial coronary artery requiring treatment (LCX or RCA), OR
  • Single vessel disease involving the LAD and a major diagonal, both requiring independent revascularization with at least one stent
  • Severe aortic stenosis/insufficiency and/or mitral stenosis/insufficiency requiring surgery, with CAD (involving one or more vessels), suitable for PCI
  • CAD with indication for revascularization with severe unilateral carotid stenosis (\>85%)
  • Ability to tolerate, and no plans to interrupt dual antiplatelet therapy (DAPT) for:
  • At least 6 months in presentation was stable CAD,
  • At least 12 months if presentation was a biomarker-positive acute coronary syndrome (ACS)
  • Willing to comply with the follow-up required by the protocol.

You may not qualify if:

  • Previous cardiac surgery of any kind
  • Previous thoracic surgery involving the left pleural space (if a left thoracotomy approach is planned)
  • Complicated or unsuccessful PCI within 30 days prior
  • Total occlusion (TIMI 0 or 1 flow) of the LM or LAD
  • Cardiogenic shock at time of screening
  • Any prior lung resection
  • End-stage renal disease on dialysis
  • Extra-cardiac illness that is expected to limit survival to less then 5 years
  • Allergy or hypersensitivity to any of the study drugs or devices used in protocol
  • Patient unable to give informed consent or potentially noncompliant with the study protocol, in the judgement of the investigator
  • Pregnant at time of screening, or unwilling to use effective birth control measures while dual antiplatelet therapy is required.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS Fondazione Policlinico Universitario Agostino Gemelli

Roma, 00168, Italy

Location

Related Publications (38)

  • Byrne JG, Leacche M, Vaughan DE, Zhao DX. Hybrid cardiovascular procedures. JACC Cardiovasc Interv. 2008 Oct;1(5):459-68. doi: 10.1016/j.jcin.2008.07.002.

    PMID: 19463346BACKGROUND
  • Leacche M, Umakanthan R, Zhao DX, Byrne JG. Surgical update: hybrid procedures, do they have a role? Circ Cardiovasc Interv. 2010 Oct;3(5):511-8. doi: 10.1161/CIRCINTERVENTIONS.110.957951. No abstract available.

    PMID: 20959598BACKGROUND
  • Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LA, Gill CC, Taylor PC, Sheldon WC, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986 Jan 2;314(1):1-6. doi: 10.1056/NEJM198601023140101.

    PMID: 3484393BACKGROUND
  • Diegeler A, Thiele H, Falk V, Hambrecht R, Spyrantis N, Sick P, Diederich KW, Mohr FW, Schuler G. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med. 2002 Aug 22;347(8):561-6. doi: 10.1056/NEJMoa013563.

    PMID: 12192015BACKGROUND
  • Lytle BW, Cosgrove DM, Loop FD, Borsh J, Goormastic M, Taylor PC. Perioperative risk of bilateral internal mammary artery grafting: analysis of 500 cases from 1971 to 1984. Circulation. 1986 Nov;74(5 Pt 2):III37-41.

    PMID: 3490331BACKGROUND
  • Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. Ann Thorac Surg. 2004 Jan;77(1):93-101. doi: 10.1016/s0003-4975(03)01331-6.

    PMID: 14726042BACKGROUND
  • Ben-Gal Y, Mohr R, Braunstein R, Finkelstein A, Hansson N, Hendler A, Moshkovitz Y, Uretzky G. Revascularization of left anterior descending artery with drug-eluting stents: comparison with minimally invasive direct coronary artery bypass surgery. Ann Thorac Surg. 2006 Dec;82(6):2067-71. doi: 10.1016/j.athoracsur.2006.06.041.

    PMID: 17126111BACKGROUND
  • Fraund S, Herrmann G, Witzke A, Hedderich J, Lutter G, Brandt M, Boning A, Cremer J. Midterm follow-up after minimally invasive direct coronary artery bypass grafting versus percutaneous coronary intervention techniques. Ann Thorac Surg. 2005 Apr;79(4):1225-31. doi: 10.1016/j.athoracsur.2004.08.082.

    PMID: 15797053BACKGROUND
  • Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2446-54. doi: 10.1001/jama.294.19.2446.

    PMID: 16287955BACKGROUND
  • Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315-23. doi: 10.1056/NEJMoa035071.

    PMID: 14523139BACKGROUND
  • Harskamp RE, Zheng Z, Alexander JH, Williams JB, Xian Y, Halkos ME, Brennan JM, de Winter RJ, Smith PK, Lopes RD. Status quo of hybrid coronary revascularization for multi-vessel coronary artery disease. Ann Thorac Surg. 2013 Dec;96(6):2268-77. doi: 10.1016/j.athoracsur.2013.07.093.

    PMID: 24446561BACKGROUND
  • Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation. 2005 Jun 28;111(25):3435-42. doi: 10.1161/CIRCULATIONAHA.104.513952. Epub 2005 Jun 20.

    PMID: 15967844BACKGROUND
  • Leacche M, Byrne JG, Solenkova NS, Reagan B, Mohamed TI, Fredi JL, Zhao DX. Comparison of 30-day outcomes of coronary artery bypass grafting surgery verus hybrid coronary revascularization stratified by SYNTAX and euroSCORE. J Thorac Cardiovasc Surg. 2013 Apr;145(4):1004-1012. doi: 10.1016/j.jtcvs.2012.03.062. Epub 2012 Apr 25.

    PMID: 22541514BACKGROUND
  • Harskamp RE, Brennan JM, Xian Y, Halkos ME, Puskas JD, Thourani VH, Gammie JS, Taylor BS, de Winter RJ, Kim S, O'Brien S, Peterson ED, Gaca JG. Practice patterns and clinical outcomes after hybrid coronary revascularization in the United States: an analysis from the society of thoracic surgeons adult cardiac database. Circulation. 2014 Sep 9;130(11):872-9. doi: 10.1161/CIRCULATIONAHA.114.009479. Epub 2014 Jul 23.

    PMID: 25055814BACKGROUND
  • Verhaegh AJ, Accord RE, van Garsse L, Maessen JG. Hybrid coronary revascularization as a safe, feasible, and viable alternative to conventional coronary artery bypass grafting: what is the current evidence? Minim Invasive Surg. 2013;2013:142616. doi: 10.1155/2013/142616. Epub 2013 Apr 3.

    PMID: 23691303BACKGROUND
  • Wrigley BJ, Dubey G, Spyt T, Gershlick AH. Hybrid revascularisation in multivessel coronary artery disease: could a combination of CABG and PCI be the best option in selected patients? EuroIntervention. 2013 Mar;8(11):1335-41. doi: 10.4244/EIJV8I11A202. No abstract available.

    PMID: 23538160BACKGROUND
  • Green KD, Lynch DR Jr, Chen TP, Zhao D. Combining PCI and CABG: the role of hybrid revascularization. Curr Cardiol Rep. 2013 Apr;15(4):351. doi: 10.1007/s11886-013-0351-9.

    PMID: 23420447BACKGROUND
  • Santana O, Funk M, Zamora C, Escolar E, Lamas GA, Lamelas J. Staged percutaneous coronary intervention and minimally invasive valve surgery: results of a hybrid approach to concomitant coronary and valvular disease. J Thorac Cardiovasc Surg. 2012 Sep;144(3):634-9. doi: 10.1016/j.jtcvs.2011.11.008. Epub 2011 Dec 10.

    PMID: 22154788BACKGROUND
  • Santana O, Pineda AM, Cortes-Bergoderi M, Mihos CG, Beohar N, Lamas GA, Lamelas J. Hybrid approach of percutaneous coronary intervention followed by minimally invasive valve operations. Ann Thorac Surg. 2014 Jun;97(6):2049-55. doi: 10.1016/j.athoracsur.2014.02.039. Epub 2014 Apr 13.

    PMID: 24725838BACKGROUND
  • Byrne JG, Leacche M, Unic D, Rawn JD, Simon DI, Rogers CD, Cohn LH. Staged initial percutaneous coronary intervention followed by valve surgery ("hybrid approach") for patients with complex coronary and valve disease. J Am Coll Cardiol. 2005 Jan 4;45(1):14-8. doi: 10.1016/j.jacc.2004.09.050.

    PMID: 15629366BACKGROUND
  • Versaci F, Reimers B, Del Giudice C, Schofer J, Giacomin A, Sacca S, Gandini R, Albiero R, Pellegrino A, Bertoldo F, Simonetti G, Chiariello L. Simultaneous hybrid revascularization by carotid stenting and coronary artery bypass grafting: the SHARP study. JACC Cardiovasc Interv. 2009 May;2(5):393-401. doi: 10.1016/j.jcin.2009.02.010.

    PMID: 19463460BACKGROUND
  • Velissaris I, Kiskinis D, Anastasiadis K. Synchronous carotid artery stenting and open heart surgery. J Vasc Surg. 2011 May;53(5):1237-41. doi: 10.1016/j.jvs.2010.11.049. Epub 2011 Jan 17.

    PMID: 21247729BACKGROUND
  • Chiariello L, Nardi P, Pellegrino A, Saitto G, Chiariello GA, Russo M, Zeitani J, Versaci F. Simultaneous carotid artery stenting and heart surgery: expanded experience of hybrid surgical procedures. Ann Thorac Surg. 2015 Apr;99(4):1291-7. doi: 10.1016/j.athoracsur.2014.11.043. Epub 2015 Feb 7.

    PMID: 25661578BACKGROUND
  • Mendiz OA, Fava CM, Lev GA, Valdivieso LR, Caponi G, Hidalgo Alava GF, Favaloro RR. Hybrid strategy for unstable patients with severe carotid and cardiac disease requiring surgery. Cardiol J. 2015;22(1):25-30. doi: 10.5603/CJ.a2014.0001. Epub 2014 Feb 14.

    PMID: 24526504BACKGROUND
  • Chiariello L, Tomai F, Zeitani J, Versaci F. Simultaneous hybrid revascularization by carotid stenting and coronary artery bypass grafting. Ann Thorac Surg. 2006 May;81(5):1883-5. doi: 10.1016/j.athoracsur.2005.04.086.

    PMID: 16631695BACKGROUND
  • Wu H, Sun H, Jiang X, Ma W, Wang X, Zhang J, Hu S. Simultaneous hybrid revascularization by peripheral artery stenting and off-pump coronary artery bypass: the early results. Ann Thorac Surg. 2011 Mar;91(3):661-4. doi: 10.1016/j.athoracsur.2010.10.057.

    PMID: 21352975BACKGROUND
  • Yang T, Zhang L, Wang X, Dong H, Jiang X, Sun H. Revascularization by carotid artery stenting and off-pump coronary artery bypass. ANZ J Surg. 2016 Jul;86(7-8):602-7. doi: 10.1111/ans.12586. Epub 2014 Apr 3.

    PMID: 24698016BACKGROUND
  • Van der Heyden J, Van Neerven D, Sonker U, Bal ET, Kelder JC, Plokker HW, Suttorp MJ. Carotid artery stenting and cardiac surgery in symptomatic patients. JACC Cardiovasc Interv. 2011 Nov;4(11):1190-6. doi: 10.1016/j.jcin.2011.07.012.

    PMID: 22115658BACKGROUND
  • Versaci F, Del Giudice C, Scafuri A, Zeitani J, Gandini R, Nardi P, Salvati A, Pampana E, Sebastiano F, Romagnoli A, Simonetti G, Chiariello L. Sequential hybrid carotid and coronary artery revascularization: immediate and mid-term results. Ann Thorac Surg. 2007 Nov;84(5):1508-13; discussion 1513-4. doi: 10.1016/j.athoracsur.2007.05.048.

    PMID: 17954054BACKGROUND
  • O'Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP; Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2--isolated valve surgery. Ann Thorac Surg. 2009 Jul;88(1 Suppl):S23-42. doi: 10.1016/j.athoracsur.2009.05.056.

    PMID: 19559823BACKGROUND
  • Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. No abstract available.

    PMID: 21670242BACKGROUND
  • Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33. doi: 10.1097/00005650-199603000-00003.

    PMID: 8628042BACKGROUND
  • Rockville, MD. Calculating the U.S. Population-based EQ-5D Index Score: Research Initiative in Clinical Economics. February 2005. Agency for Healthcare Research and Quality, http://archive.ahrq.gov/professionals/clinicians-providers/resources/rice/EQ5Dscore.html

    BACKGROUND
  • Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction; Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N. Universal definition of myocardial infarction. Circulation. 2007 Nov 27;116(22):2634-53. doi: 10.1161/CIRCULATIONAHA.107.187397. Epub 2007 Oct 19. No abstract available.

    PMID: 17951284BACKGROUND
  • Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013 Oct 22;62(17):1563-70. doi: 10.1016/j.jacc.2013.08.720.

    PMID: 24135581BACKGROUND
  • Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419. No abstract available.

    PMID: 28886622BACKGROUND
  • Sousa-Uva M, Neumann FJ, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2019 Jan 1;55(1):4-90. doi: 10.1093/ejcts/ezy289. No abstract available.

    PMID: 30165632BACKGROUND
  • Fujita B, Ensminger S, Bauer T, Mollmann H, Beckmann A, Bekeredjian R, Bleiziffer S, Schafer E, Hamm CW, Mohr FW, Katus HA, Harringer W, Walther T, Frerker C; GARY Executive Board. Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42 776 patients. Eur J Cardiothorac Surg. 2018 Mar 1;53(3):552-559. doi: 10.1093/ejcts/ezx408.

    PMID: 29190355BACKGROUND

MeSH Terms

Conditions

Coronary Artery DiseaseHeart Valve DiseasesCarotid StenosisHeart DiseasesCarotid Artery Diseases

Interventions

Coronary Artery BypassPercutaneous Coronary Intervention

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Myocardial RevascularizationCardiac Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, OperativeVascular GraftingVascular Surgical ProceduresThoracic Surgical ProceduresEndovascular ProceduresMinimally Invasive Surgical Procedures

Study Officials

  • Piergiorgio Bruno, MD

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

November 5, 2021

First Posted

December 3, 2021

Study Start

May 13, 2021

Primary Completion

July 30, 2025

Study Completion

July 30, 2025

Last Updated

August 14, 2025

Record last verified: 2025-08

Locations